Tremelimumab + Olaparib
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Peritoneal Carcinoma
Conditions
Primary Peritoneal Carcinoma
Trial Timeline
Jan 8, 2016 → Mar 5, 2020
NCT ID
NCT02485990About Tremelimumab + Olaparib
Tremelimumab + Olaparib is a phase 1 stage product being developed by AstraZeneca for Primary Peritoneal Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02485990. Target conditions include Primary Peritoneal Carcinoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02485990 | Phase 1 | Terminated |
Competing Products
20 competing products in Primary Peritoneal Carcinoma